2,131 Johnson & Johnson $JNJ Shares Sold by Brady Family Wealth LLC

Brady Family Wealth LLC lessened its position in shares of Johnson & Johnson (NYSE:JNJ) by 7.9% during the third quarter, Holdings Channel reports. The institutional investor owned 24,873 shares of the company’s stock after selling 2,131 shares during the quarter. Johnson & Johnson accounts for 2.0% of Brady Family Wealth LLC’s holdings, making the stock its 18th largest holding. Brady Family Wealth LLC’s holdings in Johnson & Johnson were worth $6,585,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of JNJ. National Pension Service grew its holdings in Johnson & Johnson by 1.3% during the 2nd quarter. National Pension Service now owns 5,226,968 shares of the company’s stock valued at $1,327,493,000 after buying an additional 67,484 shares in the last quarter. IFP Advisors Inc grew its position in shares of Johnson & Johnson by 8.8% during the 2nd quarter. IFP Advisors Inc now owns 38,760 shares of the company’s stock valued at $9,844,000 after purchasing an additional 3,133 shares in the last quarter. Elefante Mark B increased its holdings in shares of Johnson & Johnson by 9.8% in the second quarter. Elefante Mark B now owns 28,686 shares of the company’s stock worth $7,285,000 after purchasing an additional 2,563 shares during the period. AMG Asset Management Group Inc. increased its holdings in shares of Johnson & Johnson by 172.0% in the third quarter. AMG Asset Management Group Inc. now owns 3,852 shares of the company’s stock worth $1,020,000 after purchasing an additional 2,436 shares during the period. Finally, Gradient Investments LLC raised its position in shares of Johnson & Johnson by 9.9% in the second quarter. Gradient Investments LLC now owns 152,831 shares of the company’s stock worth $38,815,000 after buying an additional 13,737 shares in the last quarter. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Johnson & Johnson

In related news, EVP Jennifer Taubert sold 15,000 shares of the firm’s stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $263.36, for a total transaction of $3,950,400.00. Following the transaction, the executive vice president directly owned 194,451 shares in the company, valued at $51,210,615.36. This trade represents a 7.16% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Timothy Schmid sold 33,597 shares of the business’s stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $274.74, for a total value of $9,230,439.78. Following the completion of the sale, the executive vice president owned 25,447 shares of the company’s stock, valued at $6,991,308.78. The trade was a 56.90% decrease in their position. The SEC filing for this sale provides additional information. 0.16% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on JNJ. Citigroup lifted their price objective on Johnson & Johnson from $298.00 to $303.00 and gave the company a “buy” rating in a research note on Monday, October 5th. Argus set a $300.00 price objective on Johnson & Johnson in a report on Wednesday, July 29th. Erste Group Bank cut shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a research report on Wednesday, October 21st. Morgan Stanley lowered their target price on shares of Johnson & Johnson from $294.00 to $292.00 and set an “overweight” rating on the stock in a research note on Thursday, October 15th. Finally, Leerink Partners dropped their target price on shares of Johnson & Johnson from $276.00 to $272.00 and set an “outperform” rating for the company in a research report on Wednesday, October 14th. One research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and eight have given a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $275.92.

Key Stories Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: State Street’s Health Care SPDR added J&J shares as part of a $175.3 million purchase across its portfolio, providing a modest institutional-demand signal. Article: State Street Health Care SPDR Adds Eli Lilly and J&J
• Positive Sentiment: One analyst roundup described Wall Street as moderately bullish on J&J’s prospects, following the stock’s strong performance over the past year. Article: Are Wall Street Analysts Predicting Johnson & Johnson Stock Will Climb or Sink?
• Neutral Sentiment: Several articles highlighted J&J as a long-term dividend stock, including lists of companies with long records of annual payout increases. This supports its income-investment appeal, but the pieces offer no new company-specific dividend announcement. Article: 4 Dividend Kings That Could Pay You for the Rest of Your Retirement
• Neutral Sentiment: A value-investing comparison examined J&J alongside Bayer, while another article addressed concerns that J&J shares may look expensive; the supplied headlines do not specify a valuation conclusion. Article: BAYRY vs. JNJ: Which Stock Is the Better Value Option?
• Negative Sentiment: Smith+Nephew said merger discussions with J&J’s orthopaedics unit had failed. This removes a potential transaction, though the article headline provides no details on the talks’ terms or financial implications for J&J. Article: Smith+Nephew Cuts Outlook, Confirms Failed Merger Talks with J&J’s Orthopaedics Unit

Johnson & Johnson Price Performance

JNJ stock opened at $272.49 on Friday. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.74 and a current ratio of 1.02. Johnson & Johnson has a 52 week low of $185.12 and a 52 week high of $282.02. The firm’s fifty day moving average is $265.71 and its 200 day moving average is $248.01. The firm has a market cap of $655.97 billion, a P/E ratio of 41.29, a P/E/G ratio of 2.73 and a beta of 0.22.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, October 13th. The company reported $2.59 earnings per share for the quarter, topping the consensus estimate of $2.53 by $0.06. Johnson & Johnson had a net margin of 16.20% and a return on equity of 31.64%. The business had revenue of $25.40 billion during the quarter, compared to the consensus estimate of $25.38 billion. During the same period in the previous year, the firm posted $2.80 earnings per share. The firm’s revenue for the quarter was up 5.9% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. Research analysts predict that Johnson & Johnson will post 11.12 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 8th. Investors of record on Tuesday, November 24th will be issued a dividend of $1.34 per share. The ex-dividend date is Tuesday, November 24th. This represents a $5.36 annualized dividend and a yield of 2.0%. Johnson & Johnson’s dividend payout ratio is currently 81.21%.

Johnson & Johnson Company Profile

Johnson & Johnson (NYSE: JNJ) is a global healthcare company headquartered in New Brunswick, New Jersey. Founded in 1886, the company develops and markets products and services for patients, healthcare professionals and institutions worldwide.

Johnson & Johnson operates through two principal segments: Innovative Medicine and MedTech. Innovative Medicine focuses on pharmaceuticals for areas such as immunology, oncology, neuroscience, infectious diseases and cardiovascular conditions.